808 related articles for article (PubMed ID: 24096620)
41. Evaluation of human papillomavirus testing in primary screening for cervical abnormalities: comparison of sensitivity, specificity, and frequency of referral.
Kulasingam SL; Hughes JP; Kiviat NB; Mao C; Weiss NS; Kuypers JM; Koutsky LA
JAMA; 2002 Oct; 288(14):1749-57. PubMed ID: 12365959
[TBL] [Abstract][Full Text] [Related]
42. Cervical screening with primary HPV testing or cytology in a population of women in which those aged 33 years or younger had previously been offered HPV vaccination: Results of the Compass pilot randomised trial.
Canfell K; Caruana M; Gebski V; Darlington-Brown J; Heley S; Brotherton J; Gertig D; Jennett CJ; Farnsworth A; Tan J; Wrede CD; Castle PE; Saville M
PLoS Med; 2017 Sep; 14(9):e1002388. PubMed ID: 28926579
[TBL] [Abstract][Full Text] [Related]
43. The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.
C Kitchener H; Canfell K; Gilham C; Sargent A; Roberts C; Desai M; Peto J
Health Technol Assess; 2014 Apr; 18(23):1-196. PubMed ID: 24762804
[TBL] [Abstract][Full Text] [Related]
44. Evaluation of p16(INK4a)/Ki-67 dual stain in comparison with an mRNA human papillomavirus test on liquid-based cytology samples with low-grade squamous intraepithelial lesion.
Waldstrøm M; Christensen RK; Ørnskov D
Cancer Cytopathol; 2013 Mar; 121(3):136-45. PubMed ID: 22987560
[TBL] [Abstract][Full Text] [Related]
45. Determinants of p16/Ki-67 adequacy and positivity in HPV-positive women from a screening population.
Benevolo M; Mancuso P; Allia E; Gustinucci D; Bulletti S; Cesarini E; Carozzi FM; Confortini M; Bisanzi S; Rubino T; Rollo F; Marchi N; Farruggio A; Pusiol T; Venturelli F; Giorgi Rossi P;
Cancer Cytopathol; 2021 May; 129(5):383-393. PubMed ID: 33142029
[TBL] [Abstract][Full Text] [Related]
46. Using biomarkers as objective standards in the diagnosis of cervical biopsies.
Galgano MT; Castle PE; Atkins KA; Brix WK; Nassau SR; Stoler MH
Am J Surg Pathol; 2010 Aug; 34(8):1077-87. PubMed ID: 20661011
[TBL] [Abstract][Full Text] [Related]
47. Good performance of p16/ki-67 dual-stained cytology for surveillance of women treated for high-grade CIN.
Polman NJ; Uijterwaal MH; Witte BI; Berkhof J; van Kemenade FJ; Spruijt JW; van Baal WM; Graziosi PG; van Dijken DK; Verheijen RH; Helmerhorst TJ; Steenbergen RD; Heideman DA; Ridder R; Snijders PJ; Meijer CJ
Int J Cancer; 2017 Jan; 140(2):423-430. PubMed ID: 27677098
[TBL] [Abstract][Full Text] [Related]
48. Clinical efficacy of p16/Ki-67 dual-stained cervical cytology in secondary prevention of cervical cancer.
Celewicz A; Celewicz M; Wężowska M; Chudecka-Głaz A; Menkiszak J; Urasińska E
Pol J Pathol; 2018; 69(1):42-47. PubMed ID: 29895125
[TBL] [Abstract][Full Text] [Related]
49. p16/Ki-67 dual stain, PAP cytology and HR-HPV test results prior to and 6 months after a LLETZ procedure: a prospective observational cohort study.
Packet B; Poppe W; Vanherck M; Weynand B
Arch Gynecol Obstet; 2023 Feb; 307(2):519-524. PubMed ID: 36197541
[TBL] [Abstract][Full Text] [Related]
50. p16/Ki-67 Dual Staining Is a Reliable Biomarker for Risk Stratification for Patients With Borderline/Mild Cytology in Cervical Cancer Screening.
Magkana M; Mentzelopoulou P; Magkana E; Pampanos A; Vrachnis N; Kalafati E; Daskalakis G; Domali E; Thomakos N; Rodolakis A; Anagnou NP; Pappa KI
Anticancer Res; 2022 May; 42(5):2599-2606. PubMed ID: 35489732
[TBL] [Abstract][Full Text] [Related]
51. Triaging HPV-positive, cytology-negative cervical cancer screening results with extended HPV genotyping and p16
Song F; Yan P; Huang X; Wang C; Qu X; Du H; Wu R
BMC Infect Dis; 2021 Apr; 21(1):400. PubMed ID: 33931022
[TBL] [Abstract][Full Text] [Related]
52. Utility of p16, Ki-67, and HPV test in diagnosis of cervical intraepithelial neoplasia and atrophy in women older than 50 years with 3- to 7-year follow-up.
Jackson JA; Kapur U; Erşahin Ç
Int J Surg Pathol; 2012 Apr; 20(2):146-53. PubMed ID: 22104735
[TBL] [Abstract][Full Text] [Related]
53. Defining Optimal Triage Strategies for hrHPV Screen-Positive Women-An Evaluation of HPV 16/18 Genotyping, Cytology, and p16/Ki-67 Cytoimmunochemistry.
Stanczuk GA; Baxter GJ; Currie H; Forson W; Lawrence JR; Cuschieri K; Wilson A; Patterson L; Govan L; Black J; Palmer T; Arbyn M
Cancer Epidemiol Biomarkers Prev; 2017 Nov; 26(11):1629-1635. PubMed ID: 28887297
[No Abstract] [Full Text] [Related]
54. Clinical utility of p16/Ki67 dual-stain cytology for detection of cervical intraepithelial neoplasia grade two or worse in women with a transformation zone type 3: A cross-sectional study.
Gustafson LW; Tranberg M; Christensen PN; Brøndum R; Wentzensen N; Clarke MA; Andersen B; Petersen LK; Bor P; Hammer A
BJOG; 2023 Jan; 130(2):202-209. PubMed ID: 35686564
[TBL] [Abstract][Full Text] [Related]
55. Human papillomavirus (HPV) testing in the management of women with abnormal Pap smears. Experience of a colposcopy referral clinic.
Ciotti M; Sesti F; Paba P; Benedetto A; Patrizi L; Criscuolo A; Piccione E; Branca M; Syrjänen K; Favalli C
Eur J Gynaecol Oncol; 2004; 25(5):577-84. PubMed ID: 15493169
[TBL] [Abstract][Full Text] [Related]
56. Correlation between P16/Ki67 in cervical cytology and diagnosis of cervical intraepithelial neoplasia 2-3 in Thai women infected with high-risk types of human papillomavirus.
Srisuttayasathien M; Kantathavorn N; Luasiripanthu T; Petchjorm S; Samrarn J; Ittiamornlert P; Krisorakun W; Vanichtantikul A; Wetcho T; Saeloo S
Taiwan J Obstet Gynecol; 2024 Mar; 63(2):192-198. PubMed ID: 38485314
[TBL] [Abstract][Full Text] [Related]
57. Evaluation of p16/Ki-67 Dual-Stained Cytology in Triaging HPV-Positive Women during Cervical Cancer Screening.
Hu Y; Hong Z; Gu L; Xie L; Yang B; Dai H; Chen H; Zhang B; Huang L; Liu Z; Cheng J; Zhang Y; Zhang Y; Lin J; Qiu L; Di W
Cancer Epidemiol Biomarkers Prev; 2020 Jun; 29(6):1246-1252. PubMed ID: 32156721
[TBL] [Abstract][Full Text] [Related]
58. Comparison of CINtec PLUS cytology and cobas HPV test for triaging Canadian patients with LSIL cytology referred to colposcopy: A two-year prospective study.
Gilbert L; Ratnam S; Jang D; Alaghehbandan R; Schell M; Needle R; Ecobichon-Morris A; Wadhawan A; Costescu D; Elit L; Wang P; Zahariadis G; Chernesky M
Cancer Biomark; 2022; 34(3):347-358. PubMed ID: 35001877
[TBL] [Abstract][Full Text] [Related]
59. Risk of high-grade cervical intraepithelial neoplasia during follow-up in HPV-positive women according to baseline p16-INK4A results: a prospective analysis of a nested substudy of the NTCC randomised controlled trial.
Carozzi F; Gillio-Tos A; Confortini M; Del Mistro A; Sani C; De Marco L; Girlando S; Rosso S; Naldoni C; Dalla Palma P; Zorzi M; Giorgi-Rossi P; Segnan N; Cuzick J; Ronco G;
Lancet Oncol; 2013 Feb; 14(2):168-76. PubMed ID: 23261355
[TBL] [Abstract][Full Text] [Related]
60. Role of p16(INK4a) cytology testing as an adjunct to enhance the diagnostic specificity and accuracy in human papillomavirus-positive women within an organized cervical cancer screening program.
Gustinucci D; Passamonti B; Cesarini E; Butera D; Palmieri EA; Bulletti S; Carlani A; Staiano M; D'Amico MR; D'Angelo V; Di Dato E; Martinelli N; Malaspina M; Spita N; Tintori B; Fulciniti F
Acta Cytol; 2012; 56(5):506-14. PubMed ID: 23075891
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
